中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma

文献类型：期刊论文

作者Liu, Xiaohua1,2,6; Zhang, Yu3; Li, Yalei4; Wang, Juan3; Ding, Huaqian2,6; Huang, Wenjing3; Ding, Chunyong1,2; Liu, Hongchun4; Tan, Wenfu3; Zhang, Ao1,2,5,6,7
刊名ACTA PHARMACEUTICA SINICA B
出版日期2021-02-01
卷号11期号:2页码:488-504
关键词Medulloblastoma Hedgehog signaling pathway Drug resistance GLI BRD4
ISSN号2211-3835
DOI10.1016/j.apsb.2020.07.007
通讯作者Liu, Hongchun(hchliu@simm.ac.cn) ; Tan, Wenfu(wftan@fudan.edu.cn) ; Zhang, Ao(ao6919zhang@sjtu.edu.cn)
英文摘要Medulloblastoma (MB) is a common yet highly heterogeneous childhood malignant brain tumor, however, clinically effective molecular targeted therapy is lacking. Modulation of hedgehog (HH) signaling by epigenetically targeting the transcriptional factors GLI through bromodomain-containing protein 4 (BRD4) has recently spurred new interest as potential treatment of HH-driven MB. Through screening of current clinical BRD4 inhibitors for their inhibitory potency against glioma-associated oncogene homolog (GLI) protein, the BRD4 inhibitor 2 was selected as the lead for further structural optimization, which led to the identification of compounds 25 and 35 as the high potency HH inhibitors. Mechanism profiling showed that both compounds suppressed HH signaling by interacting with the transcriptional factor GLI, and were equally potent against the clinical resistant mutants and the wild type of smoothened (SMO) receptor with IC50 values around 1 nmol/L. In the resistant MB allograft mice, compound 25 was well tolerated and markedly suppressed tumor growth at both 5 mg/kg (TGI = 83.3%) and 10 mg/kg (TGI = 87.6%) doses. Although further modification is needed to improve the pharmacokinetic (PK) parameters, compound 25 represents an efficacious lead compound of GLI inhibitors, possessing optimal safety and tolerance to fight against HH-driven MB. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
WOS关键词DISCOVERY ; RESISTANCE ; GROWTH ; POTENT ; TRANSCRIPTION ; STRATEGIES ; VISMODEGIB ; RECURRENT
资助项目National Natural Science Foundation[81773565] ; National Natural Science Foundation[81703327] ; National Natural Science Foundation[81430080] ; National Natural Science Foundation[81573452] ; National Natural Science Foundation[81773767] ; Key Program of the Frontier Science, China of the Chinese Academy of Sciences[160621] ; Strategic Priority Research Program of the Chinese Academy of Sciences, China[XDA12020374] ; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Ministry of Education of China, Zhengzhou University, China[K2020-0012]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000617944700013
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
源URL[http://119.78.100.183/handle/2S10ELR8/295682]  
专题新药研究国家重点实验室
通讯作者Liu, Hongchun; Tan, Wenfu; Zhang, Ao
作者单位1.Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China
3.Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 201203, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med SIMM, State Key Lab Drug Res, Shanghai 201203, Peoples R China
5.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
6.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
7.Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Minist Educ China, Zhengzhou 450001, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Xiaohua,Zhang, Yu,Li, Yalei,et al. Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma[J]. ACTA PHARMACEUTICA SINICA B,2021,11(2):488-504.
APA Liu, Xiaohua.,Zhang, Yu.,Li, Yalei.,Wang, Juan.,Ding, Huaqian.,...&Zhang, Ao.(2021).Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma.ACTA PHARMACEUTICA SINICA B,11(2),488-504.
MLA Liu, Xiaohua,et al."Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma".ACTA PHARMACEUTICA SINICA B 11.2(2021):488-504.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。